Publications by authors named "Rossana Batista Oliveira Camargo-Godoy"
Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil.
Heloísa Lizotti Cilião Rossana Batista Oliveira Camargo-Godoy Marilesia Ferreira de Souza Amanda Zanuto Vinicius Daher Alvares Delfino
Mutat Res Genet Toxicol Environ Mutagen
December 2018
The immunosuppressant mycophenolic acid (MPA), derived from the prodrug mycophenolate mofetil (MMF), is a drug used widely by kidney transplant recipients. This drug selectively inhibits inosine monophosphate dehydrogenase that controls the proliferation of lymphocytes, aiding in the prevention of rejection of the transplanted organ. Polymorphisms in key genes involved in MMF metabolism may alter the function of the enzymes encoded by them and contribute to interindividual variability in the response to the drug and its efficacy.
View Article and Find Full Text PDFArticle Synopsis
- - Despite improvements in compatibility testing for organ transplants, graft rejection remains a significant issue, particularly in kidney transplants where 35% of patients experienced rejection episodes.
- - The study analyzed the impact of specific single-nucleotide polymorphisms (SNPs) in 24 genes related to metabolism, drug transport, and the immune system on graft rejection in 246 kidney transplant patients, finding notable associations with several SNPs.
- - Key SNPs identified include UGT2B7, which provides a protective effect against graft rejection, and UGT1A9 and IL23R, which increase the risk, suggesting these may serve as potential markers for assessing graft rejection risk in renal transplant patients.